Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin on kidney function in T2DM and CKD (REGROUP)
NCT04243850Phase 4Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2020
- Primary completion
- Mar 2022
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), sponsored by Amsterdam University Medical Center. Primary endpoint: measured glomerular filtration rate at 7 days. Planned start Jul 2020; status: withdrawn.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04243850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243850.